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Coronaviruses infect a wide range of mammals and birds. Their tropism is primarily determined by the ability of the spike (S) entry protein to bind to a cell surface receptor. Coronaviruses have zoonotic potential due to the adaptability of their S protein to receptors of other species, most notably demonstrated by SARS-CoV^[@CR6]^, the causative agent of the SARS epidemic, which probably originated from bats^[@CR7]^. Recently, a new coronavirus, named hCoV-EMC, has been identified in 13 patients to date with seven fatalities that suffered from severe respiratory illness, in some cases accompanied with renal dysfunction^[@CR3],[@CR4],[@CR8]^. Genetically the virus is similar to bat coronaviruses HKU4 and HKU5 and---based on phylogenetic analysis using a small fragment of the virus---to a bat coronavirus found in *Pipistrellus pipistrellus* in the Netherlands^[@CR5]^. In recent years molecular surveillance studies revealed the existence of at least 60 novel bat coronaviruses, including some closely related to SARS-CoV^[@CR9]^. As the human cases do not seem to originate from transmission from one source, the epidemiology of hCoV-EMC may be explained by a concealed circulation in the human population or by the repeated introduction from an intermediate animal host. For a better understanding of the biology of this novel coronavirus, timely identification of the receptor could reveal important clues to its zoonotic transmission potential and pathogenesis and to the design of possible intervention strategies. Two types of coronavirus protein receptors have been identified: the Betacoronavirus mouse hepatitis virus uses immunoglobulin-related carcinoembryonic antigen-related cell adhesion molecules (CEACAM)^[@CR10]^ to enter cells, whereas for several Alpha- and Betacoronaviruses, two peptidases have been identified as receptors (aminopeptidase N (APN, CD13) for hCoV-229E and several animal coronaviruses^[@CR11],[@CR12]^, and angiotensin converting enzyme 2 (ACE2) for SARS-CoV^[@CR13]^). In addition, sialic acid may act as a receptor for some coronaviruses^[@CR14]^.

Our initial experiments indicated that hCoV-EMC does not use ACE2 as an entry receptor^[@CR15]^. Therefore we first examined whether the amino-terminal receptor-binding spike domain S1 binds to cells and investigated its correlation with cell susceptibility. We expressed the S1 domain fused to the Fc region of human IgG, yielding a recombinant disulphide-bonded dimer of approximately 280 kDa ([Supplementary Fig. 1](#MOESM102){ref-type="media"}). Highly specific binding was observed to African green monkey kidney (Vero) and human liver (Huh-7) cells by immunofluorescence and fluorescence-activated cell sorting (FACS) analysis, whereas kidney cells of the *P. pipistrellus* bat showed intermediate staining ([Fig. 1](#Fig1){ref-type="fig"}). No S1 binding was detectable to COS-7 African green monkey kidney cells ([Fig. 1b](#Fig1){ref-type="fig"}). Furthermore, no specific binding to any of these cells was observed with a feline coronavirus S1 domain, whereas feline cells (*Felis catus* whole fetus, FCWF) showed strong reactivity ([Supplementary Table 1](#MOESM102){ref-type="media"}). Binding of hCoV-EMC S1 was shown to correlate with susceptibility to hCoV-EMC infection and with viral genome detection in the culture medium of infected cells ([Fig. 1](#Fig1){ref-type="fig"}). The hCoV-EMC S1 domain was demonstrated also to bind to cells from other species but its overall reactivity was more restricted compared to that observed for SARS-CoV S1 ([Supplementary Table 1](#MOESM102){ref-type="media"}).Figure 1**Binding of hCoV-EMC S1 to cells is correlated with infection of hCoV-EMC.a**--**d**, Shown in the left panels are the FACS analyses of hCoV-EMC S1--Fc binding (red line) to Vero (**a**), COS-7 (**b**), Huh-7 (**c**) and bat cells (**d**). A feline CoV S1--Fc protein (blue line) and mock-incubated cells (grey shading) were used as controls. In the middle panels, hCoV-EMC-infected cells are visualized using an antiserum that recognizes the non-structural protein NSP4. In the right panels, hCoV-EMC RNA levels in supernatants of the infected cells at 0, 20 and 40 h after infection were quantified using a TaqMan assay and expressed as genome equivalents (GE; half-maximal tissue-culture infectious dose (TCID~50~) per ml). Error bars indicate s.e.m.[PowerPoint slide](#MOESM98){ref-type="media"}

To identify the cell surface protein(s) binding to S1 we affinity-isolated proteins from Vero and Huh-7 cells using the S1--Fc chimaeric proteins. The hCoV-EMC S1--Fc protein---but not SARS-CoV S1--Fc---extracted a protein of ∼110 kDa when analysed under non-reducing conditions from Huh-7 cell lysates ([Fig. 2a](#Fig2){ref-type="fig"}). Mass spectrometric analysis identified this protein as dipeptidyl peptidase 4 (DPP4 or DPP IV, also called CD26; [Supplementary Fig. 2](#MOESM102){ref-type="media"}). Similar results were obtained using Vero cells (data not shown). We subsequently produced soluble (that is, non-membrane-anchored) forms of DPP4 and ACE2 and found that the hCoV-EMC S1--Fc protein bound the former but not the latter, whereas the opposite was seen with the SARS S1--Fc protein ([Fig. 2b](#Fig2){ref-type="fig"}). Soluble DPP4, but not soluble ACE2, inhibited infection of Vero cells by hCoV-EMC ([Supplementary Fig. 3](#MOESM102){ref-type="media"}). Moreover, transient expression of human DPP4 in the non-susceptible COS-7 cells rendered these cells susceptible to binding the hCoV-EMC S1--Fc protein to their surface ([Supplementary Fig. 4](#MOESM102){ref-type="media"}). These data indicate a direct and specific binding of hCoV-EMC S1 to human DPP4.Figure 2**hCoV-EMC S1 binding to DPP4.a**, Huh-7 cell lysates were incubated with hCoV-EMC and SARS-CoV S1--Fc proteins and affinity-isolated proteins were subjected to protein electrophoresis under non-reducing conditions. The arrowhead indicates the position of the ∼110-kDa DPP4 protein specifically isolated using the hCoV-EMC S1--Fc protein. **b**, hCoV-EMC and SARS-CoV S1--Fc proteins were mock-incubated or incubated with soluble DPP4 (sDPP4) or soluble ACE2 (sACE2) followed by protein A sepharose affinity isolation and subjected to protein electrophoresis under non-reducing conditions.[PowerPoint slide](#MOESM99){ref-type="media"}

The DPP4 protein displays high amino acid sequence conservation across different species, including the sequence that we obtained from *P. pipistrellus* bat cells ([Supplementary Fig. 5](#MOESM102){ref-type="media"}), particularly towards the carboxy-terminal end ([Supplementary Fig. 6](#MOESM102){ref-type="media"}). Next, we tested surface expression of DPP4 on susceptible and non-susceptible cells using a polyclonal human DPP4 antiserum. The specific reactivity of the anti-DPP4 serum with human and bat DPP4 was demonstrated by staining of human and bat DPP4-transfected cells ([Fig. 3a](#Fig3){ref-type="fig"}). Expression of bat DPP4 in COS-7 cells allowed hCoV-EMC S1--Fc cell surface binding ([Fig. 3a](#Fig3){ref-type="fig"}). Consistent with their susceptibility to hCoV-EMC infection and with the hCoV-EMC S1 cell surface binding, Vero and Huh-7 cells expressed high levels of DPP4 on their surface as judged by antibody reactivity, bat cells displayed low-level antibody binding, whereas COS-7 cells did not show any significant binding ([Fig. 3b](#Fig3){ref-type="fig"}). Thus, DPP4 cell surface expression on the cell lines was consistent with hCoV-EMC S1 cell surface binding and with susceptibility to hCoV-EMC infection. The relevance of these observations was enforced by the finding that DPP4 expression was also found in primary human bronchiolar epithelial cell cultures ([Fig. 3c](#Fig3){ref-type="fig"}) and in human bronchial lung tissue ([Fig. 3d](#Fig3){ref-type="fig"}), in both instances localized to the apical surfaces of non-ciliated (tubulin-IV negative) cells. In addition, hCoV-EMC infection of human bronchiolar epithelial cell cultures appeared to be localized to the non-ciliated cells that express DPP4 ([Fig. 3e](#Fig3){ref-type="fig"}).Figure 3**DPP4 is present on hCoV-EMC-susceptible cell lines and human bronchiolar epithelial cells.a**, COS-7 cells transfected with plasmids encoding human DPP4 (hDPP4), bat DPP4 (bDPP4) or a control plasmid (pcDNA) were tested for S1 binding and staining with a polyclonal antiserum against DPP4. **b**, Similarly, COS-7, Huh-7, Vero and bat cells were tested for reactivity with the same antiserum against DPP4 (blue lines) or with a control normal goat serum (grey peak). **c**, **d**, DPP4 expression (red) was also found in primary human bronchiolar epithelial cell cultures (**c**) and human bronchiolar tissue (**d**) and appeared to be localized to the apical surfaces of non-ciliated cells that do not express β-tubulin IV (green). **e**, Double-stranded viral RNA (cyan) was detected in hCoV-EMC-infected primary human bronchiolar epithelial cell cultures and appeared to be localized to non-ciliated cells that express DPP4 (red). Stainings were performed using antibodies directed against β-tubulin IV (ciliated cells; green), DPP4 (red), dsRNA (hCoV-EMC; cyan), and DAPI (cell nucleus; blue). All scale bars are 10 μm.[PowerPoint slide](#MOESM100){ref-type="media"}

To determine whether DPP4 essentially contributes to infection, susceptible cells were pre-incubated with polyclonal DPP4 antiserum before virus inoculation. Infection of Huh-7 cells was blocked by this serum but not by control serum or ACE2 antibodies, as evidenced by a strong reduction of virus infection, of virus excretion and of virus-induced cytopathic effects ([Fig. 4a](#Fig4){ref-type="fig"} and [Supplementary Fig. 7](#MOESM102){ref-type="media"}). In addition, infection of primary bronchiolar epithelial cells was blocked by the DPP4 antibodies in a dose-dependent manner ([Fig. 4b](#Fig4){ref-type="fig"}). We next examined whether DPP4 expression confers susceptibility to hCoV-EMC infection. COS-7 cells transfected with the human DPP4 expression plasmid, but not with the empty plasmid, were efficiently infected by hCoV-EMC as demonstrated by the presence of viral non-structural proteins in the cells ([Fig. 4c](#Fig4){ref-type="fig"}) and of viral RNA ([Fig. 4d](#Fig4){ref-type="fig"}) and infectious virus in the cell supernatants (not shown). Likewise, expression of bat DPP4 in COS-7 cells conferred susceptibility to the virus, although to a lesser extent ([Fig. 4c](#Fig4){ref-type="fig"}). Transfection of human DPP4 in non-susceptible cells of different species origin (feline, murine and canine) also permitted infection with hCoV-EMC ([Supplementary Fig. 8a](#MOESM102){ref-type="media"}), whereas other human coronaviruses such as hCoV-NL63, hCoV-229E and hCoV-OC43 were not able to infect human DPP4-transfected cells ([Supplementary Fig. 8b--d](#MOESM102){ref-type="media"}). Collectively, our data demonstrate that DPP4 of human and bat origin acts as a functional receptor for hCoV-EMC.Figure 4**DPP4 is essential for virus infection.a**, Inhibition of hCoV-EMC infection of Huh-7 cells by antibodies to DPP4. Supernatants collected at 2 h (open bars) and 20 h (filled bars) were tested for the presence of hCoV-EMC RNA using a TaqMan assay. Results representative of three different experiments are shown as ΔCt values (one-way ANOVA test, \**P* \< 0.05; *n* = 3 per group), normal goat, normal goat serum. **b**, Infection of human primary bronchiolar epithelial cells is blocked by the DPP4 antibodies in a dose-dependent manner and samples were analysed at 2 h (open bars) and 20 h (filled bars) after infection (one-way ANOVA test, \**P* \< 0.05; *n* = 3 per group). **c**, COS-7 cells transfected with plasmids encoding human DPP4 (hDPP4), bat DPP4 (bDPP4) or a control plasmid (pcDNA) were inoculated with hCoV-EMC at a multiplicity of infection of 1 and left for 1 h. Cells were washed twice and stained at 8 h after infection (original magnification, ×200) or supernatant collected at 2 h (open bars), 20 h (black bars) and 40 h (blue bars) was tested for the presence of hCoV-EMC RNA using a TaqMan assay (**d**). Results representative of three different experiments are expressed as GE (TCID~50~ ml^−1^) values (one-way ANOVA test, \**P* \< 0.05; *n* = 4 per group). All error bars represent s.e.m.[PowerPoint slide](#MOESM101){ref-type="media"}

After ACE2 and APN, DPP4 is the third exopeptidase to be discovered as a receptor for coronaviruses. DPP4 is a multifunctional 766-amino-acid-long type-II transmembrane glycoprotein presented in a dimeric form on the cell surface. It preferentially cleaves dipeptides from hormones and chemokines after a proline amino acid residue, thereby regulating their bioactivity^[@CR16]^. Yet the use of peptidases by coronaviruses may be more related to their abundant presence on epithelial and endothelial tissues---the primary tissues of coronavirus infection---rather than to their proteolytic activity, which in the case of APN and ACE2 appeared not to be critical for infection^[@CR12],[@CR13]^. Consistently, hCoV-EMC infection could not be blocked by the DPP4 inhibitors sitagliptin, vildagliptin, saxagliptin or P32/98 ([Supplementary Fig. 9](#MOESM102){ref-type="media"}). DPP4 also has a major role in glucose metabolism by its degradation of incretins and has been further implicated in T-cell activation, chemotaxis modulation, cell adhesion, apoptosis and regulation of tumorigenicity^[@CR16],[@CR17]^. In humans it is primarily expressed on the epithelial cells in kidney, small intestine, liver and prostate, and on activated leukocytes, whereas it occurs as a soluble form in the circulation^[@CR16],[@CR17]^. At present little is known about the tropism of hCoV-EMC *in vivo*; the virus has been detected only in upper respiratory swabs, urine, sputum and tracheal aspirate^[@CR3],[@CR4]^. Our observation of DPP4 being expressed on non-ciliated bronchial epithelial cells together with its reported expression in the kidney is consistent with clinical manifestations of hCoV-EMC infection. It is important to note that most respiratory viruses, including SARS-CoV^[@CR18]^, have a marked tropism for ciliated cells that are more widely distributed along the upper and lower respiratory tract.

The epidemiological history of hCoV-EMC remains enigmatic. As for SARS-CoV and hCoV-NL63 (refs [@CR7], [@CR19]), a bat origin possibly combined with the existence of an intermediate animal reservoir seems feasible. In view of the evolutionary conservation of DPP4 and the ability of hCoV-EMC to use bat DPP4 as a functional receptor, such host species switching would not be surprising. Adaptive mutations in the SARS-CoV S1 domain allowing improved binding to human ACE2 have been noted, explaining, at least in part, the zoonotic transmission event^[@CR20],[@CR21]^. Further in-depth characterization of the binding interface of hCoV-EMC S1 and DPP4 may shed light on the possible adaptive processes of this virus or related coronaviruses using DPP4 in novel host species.

Variations in soluble DPP4 levels in serum have been reported as clinically relevant in a number of pathophysiological conditions including type-2 diabetes mellitus and virus infections^[@CR16],[@CR17]^. It will be important to investigate whether and how varying soluble DPP4 levels affect hCoV-EMC pathogenesis. Downregulation of ACE2 expression after SARS-CoV infection has been shown to contribute to the severity of disease^[@CR22]^, consistent with the protective role of soluble ACE2 in lung injury^[@CR23]^. Given the importance of DPP4 in regulation of chemokine and cytokine responses^[@CR16]^ one may speculate that *in vivo* downregulation of the hCoV-EMC receptor may potentially influence the pathogenesis of this virus. Preliminary findings *in vitro*, however, indicate that S1 binding to DPP4 did not result in significant downregulation of DPP4 or of the DPP4 enzymatic activity on Huh-7 cells (not shown), possibly due to the observed active recycling of DPP4 from the plasma membrane^[@CR16]^. Manipulation of DPP4 levels or development of inhibitors that target the binding interface between the S1 domain and receptor *in vivo* may provide therapeutic opportunities to combat hCoV-EMC infection. In addition, future studies should address the development of effective vaccines, including those that elicit antibodies that prevent the binding of hCoV-EMC to DPP4.

Methods Summary {#Sec2}
===============

hCoV-EMC infection and detection {#Sec3}
--------------------------------

Virus stocks of hCoV-EMC were prepared as described earlier^[@CR5]^. Vero, COS-7, Huh-7 and kidney cells of the *P. pipistrellus* bat^[@CR15]^ were inoculated with hCoV-EMC for 1 h and incubated with medium containing 1% fetal bovine serum. Formaldehyde-fixed cells were stained using rabbit-anti-SARS-CoV NSP4 antibodies that are cross-reactive for hCoV-EMC, according to standard protocols using a FITC-conjugated swine-anti-rabbit antibody as a second step. Viral replication was quantified by quantitative PCR as described in Methods.

Protein expression {#Sec4}
------------------

S1 receptor-binding domains of hCoV-EMC, SARS-CoV and FIPV fused to the Fc region of human IgG, and soluble versions of DPP4 and ACE2 were expressed and purified as described in the Methods.

DPP4 cell surface expression measurement using S1--Fc proteins {#Sec5}
--------------------------------------------------------------

S1 binding of cells was measured by incubating 2.5 × 10^5^ cells with 15 μg ml^−1^ of S1--Fc followed by incubation with FITC or DyLight-488-labelled goat-anti-human IgG antibody and analysis by flow cytometry.

Online Methods {#Sec6}
==============

Protein expression {#Sec7}
------------------

A plasmid encoding hCoV-EMC S1--Fc was generated by ligating a fragment encoding the S1 domain (residues 1--747) 3′ terminally to a fragment encoding the Fc domain of human IgG into the pCAGGS expression vector. Likewise, an S1--Fc expression plasmid was made for the SARS-CoV domain S1 subunit (isolate CUHK-W1; residues 1--676), the FIPV S1 domain (isolate 79--1146; residues 1--788) and the human ACE2 ectodomain (sACE2; residues 1--614). Fc chimaeric proteins were expressed by transfection of the expression plasmids into HEK-293T cells and affinity purified from the culture supernatant using protein A sepharose beads (GE Healthcare). Purified ACE2--Fc was cleaved with thrombin and soluble ACE2 was purified by gel-filtration chromatography. A DPP4 expression vector was generated by cloning the full-length human *DPP4* gene into the pCAGGS or the pcDNA3 vector. A plasmid encoding the ectodomain of human DPP4 was generated by ligating a fragment encoding residues 39--766 of human *DPP4* into a pCD5 expression vector^[@CR24]^ encoding the signal sequence of CD5 and an OneSTrEP affinity tag (IBA GmbH). Soluble DPP4 ectodomain was prepared by transfection of the expression plasmid into HEK-293T cells and affinity purification from the culture supernatant using Strep-Tactin sepharose beads (IBA GmbH). S1 binding of cells was measured by incubating 2.5 × 10^5^ cells with 15 μg ml^−1^ of S1--Fc followed by incubation with FITC or DyLight-488-labelled goat-anti-human IgG antibody and analysis by flow cytometry.

Affinity-purification and detection of DPP4 {#Sec8}
-------------------------------------------

Huh-7 cells were washed twice with ice-cold PBS, scraped off the plastic with a rubber policeman, pelleted and lysed in ice-cold lysis buffer (0.3% n-decyl-β-[d]{.smallcaps}-maltopyranoside in PBS) containing protease inhibitors (Roche Complete Mini and phenylmethylsulphonyl fluoride) at a final density of ∼2.5 × 10^7^ cells ml^−1^. The supernatants of centrifuged cell lysates were precleared with protein A sepharose beads after which 10 μg of S1--Fc and 100 μl protein A sepharose beads (50% v/v) was added to 1 ml of cell lysate and incubated for 1 h at 4 °C under rotation. Beads were washed thrice with lysis buffer and once with PBS and subjected to protein electrophoresis (NoVEX 4--12% Tris-glycine gradient gel, Invitrogen) under non-reducing conditions. A distinct ∼110-kDa protein co-purified with hCoV-EMC S1--Fc was visualized by GelCodeBlue staining, excised from the gel, incubated with trypsin and analysed by mass spectrometry.

Mass spectrometry and data analysis {#Sec9}
-----------------------------------

The distinct ∼110-kDa protein which co-purified with hCoV-EMC S1--Fc was excised from the gel and subjected to in-gel reduction with dithiothreitol, alkylation with chloroacetamide and digestion with trypsin (Promega, sequencing grade), essentially as described^[@CR25]^. Alternatively, affinity-isolated proteins were reduced and alkylated on beads similarly as described above. Nanoflow LC-MS/MS was performed on either an 1100 series capillary LC system (Agilent Technologies) coupled to an LTQ-Orbitrap XL mass spectrometer (Thermo), or an EASY-nLC coupled to a Q Exactive mass spectrometer (Thermo), operating in positive mode and equipped with a nanospray source. Peptide mixtures were trapped on a ReproSil C18 reversed-phase column (Dr Maisch GmbH; column dimensions 1.5 cm × 100 µm, packed in-house) at a flow rate of 8 µl min^−1^. Peptide separation was performed on ReproSil C18 reversed-phase column (Dr Maisch GmbH; column dimensions 15 cm × 50 μm, packed in-house) using a linear gradient from 0% to 80% B (A = 0.1% formic acid; B = 80% (v/v) acetonitrile, 0.1% formic acid) in 70 or 120 min and at a constant flow rate of 200 nl min^−1^. The column eluent was directly sprayed into the ESI source of the mass spectrometer. Mass spectra were acquired in continuum mode; fragmentation of the peptides was performed in data-dependent mode by CID or HCD. Peak lists were automatically created from raw data files using the Mascot Distiller software (version 2.3; MatrixScience) or Proteome Discoverer (version 1.3; Thermo). The Mascot algorithm (version 2.2; MatrixScience) was used for searching against a Uniprot database (release 2012_10.fasta, taxonomy: *Homo sapiens* or *Chlorocebus sabaeus*). The peptide tolerance was set to 10 p.p.m. and the fragment ion tolerance was set to 0.8 Da for CID spectra (LTQ-Orbitrap) or to 20 milli unified atomic mass unit (mu) for HCD (Q Exactive) spectra. A maximum number of two missed cleavages by trypsin were allowed and carbamidomethylated cysteine and oxidized methionine were set as fixed and variable modifications, respectively.

Blocking of hCoV-EMC replication by DPP4 antiserum {#Sec10}
--------------------------------------------------

Huh-7 and primary airway epithelial cells (triplicates of one donor) were pre-incubated with antibodies to DPP4 (polyclonal goat-anti DPP4 immunoglobulin, R&D systems) in a range of 0--20 µg ml^−1^. Cells were infected with hCoV-EMC, incubated for 1 h at 37 °C, washed and subsequently incubated with medium containing the respective antibody concentrations. Supernatants were collected at 2 h and 20 h and were analysed for the presence of hCoV-EMC RNA using a real-time Taqman assay.

Human bronchial epithelial cultures and confocal microscopy analysis {#Sec11}
--------------------------------------------------------------------

Human bronchial lung tissue was obtained from patients (age \>18 years old) who underwent surgical lung resection in their diagnostic pathway for any pulmonary disease and that gave informed consent. This was done in accordance with local regulation of the Kantonal Hospital St Gallen, Switzerland, as part of the St Gallen Lung Biopsy Biobank (SGLBB) which received approval by the ethics committee of the Kanton St Gallen (EKSG 11/044, 27 April 2011; and EKSG 11/103, 23 September 2011).

Primary human bronchial epithelial cultures were generated as previously described^[@CR26]^. Human bronchial epithelial cultures were maintained for 1--2 months until pseudostratified and fully differentiated epithelia were obtained. Human bronchial tissue or human bronchial epithelial cultures were fixed with 4% PFA (FormaFix) for 30 min at room temperature. The fixed human bronchial tissue or cultures were mounted in Tissue-Tek OCT medium and snap frozen in liquid nitrogen, from which 10 µm horizontal sections were made. The cryosections were immunostained using the procedure as described^[@CR26]^, using mouse monoclonal antibody anti-β-tubulin IV (Sigma) and goat anti-hDPP4 polyclonal antibody (R&D Systems) as primary antibodies, and Dylight-488-labelled, anti-mouse IgG (H+L) and Dylight-549-labelled, anti-goat IgG (H+L) as secondary antibodies (Jackson ImmunoResearch). Counterstaining was done with DAPI (Invitrogen). Fluorescent images were acquired using Plan Apochromat 63×/1.40 oil DIC M27 or EC Plan-Neofluor 40×/1.30 oil DIC M27 objectives on a Zeiss LSM 710 confocal microscope. Image capture, analysis and processing were performed using the ZEN 2010 (Zeiss) software packages.

hCoV-EMC-infected human bronchial epithelial cultures were fixed with 4% PFA (FormaFix) for 30 min at room temperature. Fixed cultures were immunostained using the procedure as described^[@CR26]^, with mouse monoclonal antibody anti-dsRNA (J2, English and Scientific Consulting Bt.) and goat anti-hDPP4 polyclonal antibody (R&D Systems) as primary antibodies, and Dylight-488-labelled, anti-mouse IgG (H+L) and Dylight-549-labelled, anti-goat IgG (H+L) as secondary antibodies (Jackson ImmunoResearch). The rabbit monoclonal anti-β-tubulin conjugated with Alexafluor 647 (9F3, Cell Signaling) was applied as tertiary antibody. Counterstaining was done with DAPI (Invitrogen). *Z*-stack images were acquired using a Plan Apochromat 63×/1.40 oil DIC M27 objective on a Zeiss LSM 710 confocal microscope from which a three-dimensional reconstruction was made using maximum intensity projection. Image capture, analysis and processing were performed using the ZEN 2010 (Zeiss) and Imaris (Bitplane Scientific Software) software packages.

DPP4 enzymatic activity {#Sec12}
-----------------------

DPP4 activity was measured on live cells using DPPIV/CD26 Assay kit for Biological Samples (Enzo Life sciences). Briefly, Vero cells (1 × 10^4^ cells well^−1^) were grown in 96-well plates, washed twice with PBS, incubated with or without inhibitor (20 µg ml^−1^) for 10 min after which H-Gly-Pro-AMC substrate was added and incubated for 10 min. Fluorescence intensity was measured at 380/460 nm using Tecan Infinite F200.

Cloning and expression of human and bat DPP4 {#Sec13}
--------------------------------------------

Total RNA was isolated from Huh-7 and PipNi/1 cells using RNeasy mini kit (Qiagen) and cDNAs were synthesized by using the Superscript reverse transcriptase (Life Technologies). The complete *DPP4* genes were amplified using Pfu Ultra II fusion HS DNA polymerase (Stratagene) and cloned into the pcDNA 3.1 (+) expression vector (Life Technologies). After sequencing, alignment was performed using ClustalW in the MEGA 5.0 software package (<http://www.megasoftware.net>) and the trees were constructed by using the neighbour-joining method with *p*-distance (gap/missing data treatment; complete deletion) and 1,000 bootstrap replicates as in MEGA 5.0. pcDNA plasmids containing the human or bat DPP4 or the empty pcDNA plasmid were transfected into COS-7 cells using lipofectamine 2000 (Life technologies). After 24 h incubation, cells were stained with both goat-anti-human DPP4 polyclonal antibody (R&D system) and a rabbit anti-goat IgG--FITC antibody (Sigma).

Virus infection, RNA extraction and quantitative RT--PCR {#Sec14}
--------------------------------------------------------

Virus stocks of hCoV-EMC were prepared as described previously^[@CR5]^. Vero, COS-7, Huh-7 and kidney cells of the *P. pipistrellus* bat cells^[@CR15]^ were inoculated with hCoV-EMC for 1 h and incubated with medium containing 1% fetal bovine serum. Formaldehyde-fixed cells were stained using rabbit-anti-SARS-CoV NSP4 antibodies that are cross-reactive for hCoV-EMC, according to standard protocols using a FITC-conjugated swine-anti-rabbit antibody as a second step. RNA from 200 μl of culture supernatant was isolated with the Magnapure LC total nucleic acid isolation kit (Roche) and eluted in 100 μl. hCoV-EMC RNA was quantified on the ABI prism 7700, with the TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems) using 20 μl isolated RNA, 1× Taqman mix, 0.5 U uracil-*N*-glycosylase, 45 pmol forward primer (5′-GGGTGTACCTCTTAATGCCAATTC-3′), 45 pmol reverse primer (5′-TCTGTCCTGTCTCCGCCAAT-3′) and 5 pmol probe (5′-FAM-ACCCCTGCGCAAAATGCTGGG-BHQ1-3′) . Amplification parameters were 5 min at 50 °C, 20 s at 95 °C, and 45 cycles of 3 s at 95 °C, and 30 s at 60 °C. RNA dilutions isolated from an hCoV-EMC stock were used as a standard. hCoV-NL63, hCoV-229E and hCoV-OC43 quantitative PCRs were routinely performed at the diagnostics Department of Viroscience at the Erasmus MC Rotterdam.

Statistics {#Sec15}
----------

We compared the mean Ct values and log GE hCoV-EMC using one-way ANOVA with post-test Bonferroni. Statistical analysis was performed with Prism 4.0 (Graphpad).
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GenBank/EMBL/DDBJ[KC249974](http://www.ncbi.nlm.nih.gov/nuccore/?term=KC249974)

Data deposits {#d29e995}
=============

The *P. pipistrellus* bat *DPP4* sequence has been deposited in GenBank/EMBL/DDBJ under accession number [KC249974](http://www.ncbi.nlm.nih.gov/nuccore/?term=KC249974).
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